PAR4 Overexpression Promotes Colorectal Cancer Cell Proliferation and Migration

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Oct 19

PMID 30333860

Citations 8

Authors

Hongshan Zhang

Ping Jiang

Chuanrao Zhang

Siman Lee

Wei Wang

Hao Zou

Affiliations

Soon will be listed here.

Abstract

Protease-activated receptor 4 (PAR4), a member of the G-protein-coupled receptor family, was previously identified to be involved in the progression of cancer. Previous study revealed that the expression of PAR4 was increased in colorectal cancer tissues compared with the associated normal tissues, particularly in positive lymph node and poorly differentiated types of cancer. We hypothesized that PAR4 serves a function in the progression of colorectal cancer. In the present study, overexpression of PAR4 in colorectal cancer LoVo cells promoted proliferation, anchorage-independent growth and migration. , PAR4 increased LoVo cell tumorgenicity. In contrast, knockdown of PAR4 in HT-29 cells decreased proliferation, anchorage-independent growth and migration. Mechanistic studies revealed that PAR4 increased the phosphorylation of extracellular-signal-regulated kinase 1/2 in colorectal cancer cells, which is the potential molecular mechanism that promotes cellular proliferation and migration. Taken together, the results of the present study indicated that overexpression of PAR4 promoted colorectal cancer cell proliferation, survival and metastasis, indicating that PAR4 is a promising therapeutic target for preventing colon cancer progression.

Citing Articles

Endothelial protease-activated receptor 4: impotent or important?.

Rajala R, Griffin C Front Cardiovasc Med. 2025; 12:1541879.

PMID: 39935714 PMC: 11810968. DOI: 10.3389/fcvm.2025.1541879.

Regulators of G-Protein Signaling (RGS) in Sporadic and Colitis-Associated Colorectal Cancer.

Swierczynski M, Kasprzak Z, Makaro A, Salaga M Int J Mol Sci. 2024; 25(1).

PMID: 38203748 PMC: 10778579. DOI: 10.3390/ijms25010577.

PARs in the inflammation-cancer transformation of CRC.

Lv J, Liu J, Chao G, Zhang S Clin Transl Oncol. 2022; 25(5):1242-1251.

PMID: 36547764 DOI: 10.1007/s12094-022-03052-x.

Expression profiling of anticancer genes in colorectal cancer patients and their in vitro induction by riproximin, a ribosomal inactivating plant protein.

Pervaiz A, Saleem T, Kanwal K, Raza S, Iqbal S, Zepp M J Cancer Res Clin Oncol. 2022; 149(8):4825-4837.

PMID: 36251065 DOI: 10.1007/s00432-022-04410-6.

Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy.

Strasenburg W, Jozwicki J, Durslewicz J, Kuffel B, Kulczyk M, Kowalewski A Front Oncol. 2022; 12:909767.

PMID: 35814405 PMC: 9259835. DOI: 10.3389/fonc.2022.909767.

References

Kaufmann R, Rahn S, Pollrich K, Hertel J, Dittmar Y, Hommann M . Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol. 2007; 211(3):699-707. DOI: 10.1002/jcp.21027. View

Macfarlane S, Seatter M, Kanke T, HUNTER G, Plevin R . Proteinase-activated receptors. Pharmacol Rev. 2001; 53(2):245-82. View

Yu G, Lee Y, Cheng C, Wu C, Song J, Gallick G . RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res. 2014; 13(2):348-57. PMC: 4336832. DOI: 10.1158/1541-7786.MCR-14-0384-T. View

Zhang Y, Yu G, Wang Y, Xiang Y, Gao Q, Jiang P . Activation of protease-activated receptor (PAR) 1 by frog trefoil factor (TFF) 2 and PAR4 by human TFF2. Cell Mol Life Sci. 2011; 68(22):3771-80. PMC: 11115081. DOI: 10.1007/s00018-011-0678-6. View

Kataoka H, Hamilton J, McKemy D, Camerer E, Zheng Y, Cheng A . Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood. 2003; 102(9):3224-31. DOI: 10.1182/blood-2003-04-1130. View

Bretschneider E, Kaufmann R, Braun M, Nowak G, Glusa E, Schror K . Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. Br J Pharmacol. 2001; 132(7):1441-6. PMC: 1572688. DOI: 10.1038/sj.bjp.0703947. View

Greenberg D, Mize G, Takayama T . Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells. Biochemistry. 2003; 42(3):702-9. DOI: 10.1021/bi027100x. View

Smith T, Coronel L, Li J, Dores M, Nieman M, Trejo J . Protease-activated Receptor-4 Signaling and Trafficking Is Regulated by the Clathrin Adaptor Protein Complex-2 Independent of β-Arrestins. J Biol Chem. 2016; 291(35):18453-64. PMC: 5000090. DOI: 10.1074/jbc.M116.729285. View

Sambrano G, Weiss E, Zheng Y, Huang W, Coughlin S . Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001; 413(6851):74-8. DOI: 10.1038/35092573. View

10.

Lengauer C, Kinzler K, Vogelstein B . Genetic instabilities in human cancers. Nature. 1999; 396(6712):643-9. DOI: 10.1038/25292. View

11.

Huang Y, Li J, Karpatkin S . Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. J Biol Chem. 2000; 275(9):6462-8. DOI: 10.1074/jbc.275.9.6462. View

12.

Center M, Jemal A, Smith R, Ward E . Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009; 59(6):366-78. DOI: 10.3322/caac.20038. View

13.

Cottrell S, Bicknell D, Kaklamanis L, Bodmer W . Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet. 1992; 340(8820):626-30. DOI: 10.1016/0140-6736(92)92169-g. View

14.

Elste A, Petersen I . Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer. J Mol Histol. 2010; 41(2-3):89-99. DOI: 10.1007/s10735-010-9274-6. View

15.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

16.

Yu G, Jiang P, Xiang Y, Zhang Y, Zhu Z, Zhang C . Increased expression of protease-activated receptor 4 and Trefoil factor 2 in human colorectal cancer. PLoS One. 2015; 10(4):e0122678. PMC: 4395443. DOI: 10.1371/journal.pone.0122678. View

17.

Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M . Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol. 2003; 162(5):1503-13. PMC: 1851194. DOI: 10.1016/S0002-9440(10)64283-6. View

18.

Gratio V, Walker F, Lehy T, Laburthe M, Darmoul D . Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. Int J Cancer. 2008; 124(7):1517-25. DOI: 10.1002/ijc.24070. View

19.

Lee S, Jiang P, Wang W, Feng W, Yu G . The decreased expression of protease-activated receptor 4 in esophageal squamous carcinoma. Neoplasma. 2014; 61(5):546-52. DOI: 10.4149/neo_2014_067. View

20.

Booden M, Eckert L, Der C, Trejo J . Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol. 2004; 24(5):1990-9. PMC: 350540. DOI: 10.1128/MCB.24.5.1990-1999.2004. View